Vil­i­fied for high drug prices, what does the prof­itabil­i­ty of ma­jor US phar­ma com­pa­nies look like?

Health care is a hu­man right, not a priv­i­lege, glob­al pol­i­cy­mak­ers like to un­der­score. But in prac­tice in the Unit­ed States, af­ford­abil­i­ty is one of the most cru­cial hur­dles to ac­cess­ing care. As the clar­i­on call to low­er US drug prices hits deaf­en­ing heights, a new study sug­gests that ma­jor drug­mak­ers aren’t nec­es­sar­i­ly rak­ing in more prof­its than oth­er in­dus­tries that al­so de­pend on sci­ence and tech­nol­o­gy to de­vel­op their of­fer­ings.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.